Concepedia

Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab

Doran Ksienski, Pauline T. Truong, Nicole S. Croteau, Angela Chan, Eric Sonke, Tiffany Patterson, Melissa Clarkson, Samuel Hackett, Mary Lesperance

Journal of Geriatric Oncology · 2021 · 13 citations · 24 references

DOI

Concepts

References

24

R: A Language and Environment for Statistical Computing

R Core Team · 2000 · 353K citations · Full text

, , +10

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Mary E. Charlson, Peter Pompei, Kathy L. Aleš et al. · Journal of Chronic Diseases · 1987 · 49.9K citations

, , +15

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

, , +17

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

, , +17

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

, , +14